Head-To-Head Comparison: Bullfrog AI (NASDAQ:BFRG) and SOPHiA GENETICS (NASDAQ:SOPH)

Bullfrog AI (NASDAQ:BFRG) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Risk and Volatility

Bullfrog AI has a beta of -3, suggesting that its stock price is 400% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Bullfrog AI and SOPHiA GENETICS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Earnings and Valuation

This table compares Bullfrog AI and SOPHiA GENETICS”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$116,670.00	79.89	-$6.50 million	($0.54)	-1.36
SOPHiA GENETICS	$77.27 million	4.39	-$79.00 million	($0.52)	-9.52

Bullfrog AI has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Bullfrog AI and SOPHiA GENETICS, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1	0	0	0	1.00
SOPHiA GENETICS	1	0	2	0	2.33

SOPHiA GENETICS has a consensus price target of $7.50, suggesting a potential upside of 51.48%. Given SOPHiA GENETICS’s stronger consensus rating and higher possible upside, analysts clearly believe SOPHiA GENETICS is more favorable than Bullfrog AI.

Institutional & Insider Ownership

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 25.2% of Bullfrog AI shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

SOPHiA GENETICS beats Bullfrog AI on 9 of the 14 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.